Avidity Biosciences (RNA) Stock Forecast & Price Target

Compare

785 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RNA Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Avidity

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RNA Stock 12 Month Forecast

Average Price Target

$66.21

▲(125.82%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $66.21 with a high forecast of $78.00 and a low forecast of $54.00. The average price target represents a 125.82% change from the last price of $29.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","52":"$52","79":"$79","38.5":"$38.5","65.5":"$65.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$66.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,38.5,52,65.5,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.17,36.61846153846154,40.066923076923075,43.51538461538462,46.963846153846156,50.41230769230769,53.860769230769236,57.30923076923077,60.75769230769231,64.20615384615385,67.65461538461538,71.10307692307693,74.55153846153846,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.17,35.71153846153846,38.253076923076925,40.79461538461538,43.33615384615385,45.87769230769231,48.419230769230765,50.96076923076923,53.50230769230769,56.04384615384615,58.58538461538461,61.12692307692307,63.66846153846153,{"y":66.21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.17,34.77230769230769,36.37461538461539,37.97692307692308,39.57923076923077,41.181538461538466,42.783846153846156,44.386153846153846,45.988461538461536,47.59076923076923,49.19307692307692,50.79538461538462,52.39769230769231,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.86,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.28,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.57,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$78.00

Average Price Target$66.21

Lowest Price Target$54.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$32

Hold

9.14%

Upside

Reiterated

06/14/25

Avidity Biosciences' stock score is primarily driven by promising corporate developments in clinical trials, which strengthen its growth prospects. However, financial performance, including profitability and cash flow challenges, and a weak valuation due to negative earnings, weigh down the overall score.

Gena WangBarclays

Barclays

$59

Buy

101.23%

Upside

Reiterated

06/18/25

Avidity Biosciences (RNA) Receives a Buy from Barclays

Tazeen AhmadBank of America Securities

Bank of America Securities

$54

Buy

84.17%

Upside

Reiterated

06/17/25

Avidity Biosciences Positioned for Market Leadership with Promising DM1 Treatment in Phase 3 Trial

Yanan ZhuWells Fargo

Wells Fargo

$70

Buy

138.74%

Upside

Reiterated

06/17/25

Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating

Andy ChenWolfe Research

Wolfe Research

$55

Buy

87.59%

Upside

Initiated

06/16/25

Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research

Joseph SchwartzLeerink Partners

Leerink Partners

$60→$65

Buy

121.69%

Upside

Reiterated

06/13/25

Avidity Biosciences price target raised to $65 from $60 at LeerinkAvidity Biosciences price target raised to $65 from $60 at Leerink

Ritu BaralTD Cowen

TD Cowen

$78

Buy

166.03%

Upside

Reiterated

06/13/25

TD Cowen Keeps Their Buy Rating on Avidity Biosciences (RNA)

Geoff MeachamCiti

Citi

$70→$75

Buy

155.80%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA), Danaher (NYSE: DHR) and Ascendis Pharma (NASDAQ: ASND)

Michael W. FreemanRaymond James

Raymond James

$65

Buy

121.69%

Upside

Initiated

06/10/25

Avidity Biosciences initiated with a Strong Buy at Raymond JamesAvidity Biosciences initiated with a Strong Buy at Raymond James

Louise ChenScotiabank

Scotiabank

$70

Buy

138.74%

Upside

Reiterated

06/10/25

Avidity Biosciences (RNA) Receives a Buy from Scotiabank

Keay NakaeChardan Capital

Chardan Capital

$75

Buy

155.80%

Upside

Reiterated

06/09/25

Analysts' Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)

Joseph StringerNeedham

Needham

$60

Buy

104.64%

Upside

Reiterated

06/09/25

Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$68

Buy

131.92%

Upside

Reiterated

06/09/25

Avidity data strengthens accelerated approval case, says H.C. WainwrightAvidity data strengthens accelerated approval case, says H.C. Wainwright

Kostas BiliourisBMO Capital

BMO Capital

$72

Buy

145.57%

Upside

Reiterated

06/09/25

Avidity Biosciences: Promising Developments and FDA Endorsement Position for Potential Regulatory Approvals by 2027

Luca IssiRBC Capital

RBC Capital

$61

Buy

108.05%

Upside

Reiterated

05/08/25

RBC Capital Sticks to Its Buy Rating for Avidity Biosciences (RNA)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$32

Hold

9.14%

Upside

Reiterated

06/14/25

Gena WangBarclays

Barclays

$59

Buy

101.23%

Upside

Reiterated

06/18/25

Avidity Biosciences (RNA) Receives a Buy from Barclays

Tazeen AhmadBank of America Securities

Bank of America Securities

$54

Buy

84.17%

Upside

Reiterated

06/17/25

Avidity Biosciences Positioned for Market Leadership with Promising DM1 Treatment in Phase 3 Trial

Yanan ZhuWells Fargo

Wells Fargo

$70

Buy

138.74%

Upside

Reiterated

06/17/25

Avidity Biosciences: Strong Market Position and Future Potential Justify Buy Rating

Andy ChenWolfe Research

Wolfe Research

$55

Buy

87.59%

Upside

Initiated

06/16/25

Avidity Biosciences initiated with an Outperform at Wolfe ResearchAvidity Biosciences initiated with an Outperform at Wolfe Research

Joseph SchwartzLeerink Partners

Leerink Partners

$60→$65

Buy

121.69%

Upside

Reiterated

06/13/25

Avidity Biosciences price target raised to $65 from $60 at LeerinkAvidity Biosciences price target raised to $65 from $60 at Leerink

Ritu BaralTD Cowen

TD Cowen

$78

Buy

166.03%

Upside

Reiterated

06/13/25

TD Cowen Keeps Their Buy Rating on Avidity Biosciences (RNA)

Geoff MeachamCiti

Citi

$70→$75

Buy

155.80%

Upside

Reiterated

06/10/25

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (NASDAQ: RNA), Danaher (NYSE: DHR) and Ascendis Pharma (NASDAQ: ASND)

Michael W. FreemanRaymond James

Raymond James

$65

Buy

121.69%

Upside

Initiated

06/10/25

Avidity Biosciences initiated with a Strong Buy at Raymond JamesAvidity Biosciences initiated with a Strong Buy at Raymond James

Louise ChenScotiabank

Scotiabank

$70

Buy

138.74%

Upside

Reiterated

06/10/25

Avidity Biosciences (RNA) Receives a Buy from Scotiabank

Keay NakaeChardan Capital

Chardan Capital

$75

Buy

155.80%

Upside

Reiterated

06/09/25

Analysts' Top Healthcare Picks: Amicus (FOLD), Inspire Medical Systems (INSP)

Joseph StringerNeedham

Needham

$60

Buy

104.64%

Upside

Reiterated

06/09/25

Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway

Ananda GhoshH.C. Wainwright

H.C. Wainwright

$68

Buy

131.92%

Upside

Reiterated

06/09/25

Avidity data strengthens accelerated approval case, says H.C. WainwrightAvidity data strengthens accelerated approval case, says H.C. Wainwright

Kostas BiliourisBMO Capital

BMO Capital

$72

Buy

145.57%

Upside

Reiterated

06/09/25

Avidity Biosciences: Promising Developments and FDA Endorsement Position for Potential Regulatory Approvals by 2027

Luca IssiRBC Capital

RBC Capital

$61

Buy

108.05%

Upside

Reiterated

05/08/25

RBC Capital Sticks to Its Buy Rating for Avidity Biosciences (RNA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avidity Biosciences

1 Month

xxx

Success Rate

13/23 ratings generated profit

Average Return

+3.16%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +3.16% per trade.

3 Months

xxx

Success Rate

8/14 ratings generated profit

Average Return

+9.14%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.14% per trade.

1 Year

Yanan ZhuWells Fargo

Success Rate

11/23 ratings generated profit

Average Return

+110.27%

reiterated a buy rating 3 days ago

Copying Yanan Zhu's trades and holding each position for 1 Year would result in 47.83% of your transactions generating a profit, with an average return of +110.27% per trade.

2 Years

xxx

Success Rate

17/24 ratings generated profit

Average Return

+98.06%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.83% of your transactions generating a profit, with an average return of +98.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RNA Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RNA has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RNA average Analyst price target in the past 3 months is 66.21.

Each month's total comprises the sum of three months' worth of ratings.

RNA Financial Forecast

RNA Earnings Forecast

Next quarter’s earnings estimate for RNA is -$0.95 with a range of -$1.33 to -$0.55. The previous quarter’s EPS was -$0.90. RNA beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.

RNA Sales Forecast

Next quarter’s sales forecast for RNA is $1.48M with a range of $0.00 to $3.89M. The previous quarter’s sales results were $1.57M. RNA beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year RNA has Outperformed its overall industry.

RNA Stock Forecast FAQ

What is RNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is 66.21.

What is RNA’s upside potential, based on the analysts’ average price target?

Avidity Biosciences Inc has 125.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RNA a Buy, Sell or Hold?

Avidity Biosciences Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Avidity Biosciences Inc’s price target?

The average price target for Avidity Biosciences Inc is 66.21. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $78.00 ,the lowest forecast is $54.00. The average price target represents 125.82% Increase from the current price of $29.32.

What do analysts say about Avidity Biosciences Inc?

Avidity Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of RNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Avidity Biosciences (RNA) Stock Forecast & Price Target

RNA Analyst Ratings

RNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Avidity Biosciences

RNA Analyst Recommendation Trends

RNA Financial Forecast

RNA Earnings Forecast

RNA Sales Forecast

RNA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts